Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

Share Price is delayed by 15 minutes
Get Live Data
2,828.00    0.00 (0.00%)
Bid:
2,170.00
Ask:
3,000.00
Spread: 830.00 (38.249%)
Market Cap: £6.73b
IMI Live PriceLast checked at - London Stock Exchange

Intraday IMI Share Chart

Trading Update

12 May 2026 07:00

RNS Number : 8526D
IMI PLC
12 May 2026
Β 

12 May 2026

Β 

Good first quarter performance

On track to deliver a sixth consecutive year of mid-single-digit organic revenue growth

Full year guidance reconfirmed

Β 

IMI plc ("IMI"), a global leader in fluid and motion control, issues the following trading update which covers results for the first quarter from 1 January to 31 March 2026.

Β 

Roy Twite, Chief Executive, commented:

Β 

"We have made a good start to the year, delivering organic growth across IMI in the first quarter. Our performance reflects the strength of the One IMI operating model and the benefits of our strategic focus on three megatrends - Energy, Automation and Healthcare - which are creating sustained demand across our markets and underpinning our long-term growth.

Β 

We are pleased to be reconfirming our full‑year guidance and remain on track to deliver our sixth consecutive year of mid‑single-digit organic revenue growth in 2026.

Β 

We are actively monitoring the situation in the Middle East, where the safety of our people remains our top priority. The region represented 6% of IMI's revenue in 2025, principally within Process Automation.

Β 

IMI remains well positioned, with a unique market-led approach to innovation, significant recurring high-margin aftermarket exposure and strong pricing power. Our strong balance sheet and significant cash generation continue to support investment, shareholder returns and strategic flexibility."

Β 

First quarter performance

Β 

First quarter organic revenue was 5% higher year on year. Statutory revenue in the quarter was 6% higher than last year, reflecting foreign currency movements in the period.

Β 

Automation

Β 

Automation (65% of 2025 sales) delivered organic revenue growth of 6% in the quarter.

Β 

Β· Process Automation (44% of 2025 sales) organic revenue was up 6% in the period. As expected, total orders were down 2% organically year-on-year, against a strong comparator. Aftermarket orders declined by 1%, reflecting several large nuclear Aftermarket orders won in the first quarter of last year as previously highlighted. Whilst the conflict in the Middle East did lead to some disruption in the region during the first quarter, the effect on orders and sales was not significant. We continue to see a strong pipeline of global opportunities, driven by the rapidly increasing demand for energy from data centres and widespread electrification.

Β 

Β· Industrial Automation (21% of 2025 sales) organic revenue increased by 6% year on year, benefiting from an easier comparator following the cyber incident in the first quarter of 2025. Industrial Automation is expected to be modestly higher organically in 2026.

Β 

Life Technology

Β 

Life Technology (35% of 2025 sales) organic revenue increased by 4% in the first quarter.

Β 

Β· Climate Control (18% of 2025 sales) organic revenue grew by 4% compared to the same period last year. Demand for energy‑efficient solutions remained supportive, including continued strength in the data centre direct liquid cooling market.

Β 

Β· Life Science and Fluid Control (10% of 2025 sales) organic revenue increased by 1% in the first quarter. Growth in Life Science was supported by resilient healthcare demand and further signs of stabilisation in the global life science device market. This was partially offset by the impact of mixed market conditions in Fluid Control.

Β 

Β· Transport (7% of 2025 sales) organic revenue was 9% higher year on year, in line with the heavy‑duty truck market. The strategic review of Transport is progressing; we are delivering significant operational improvements and continue to assess all strategic options.

Β 

Exchange rates

Β 

If exchange rates as at 1 May 2026 of US$1.36 and €1.16 remain constant for the remainder of the year, it would have no material impact on revenue and adjusted operating profit in the full year when compared to 2025.

Β 

Full year guidance reconfirmed

Β 

Following the good first quarter performance, we are reconfirming our full year guidance and remain on track to deliver our sixth consecutive year of mid-single-digit organic revenue growth in 2026. We continue to expect that full year adjusted basic earnings per share will be between 136p and 142p.

Β 

Our guidance assumes that conditions allow for planned shipments to the Middle East to be delivered by the end of the financial year. Whilst we remain alert to the potential indirect impact of the conflict, we expect to manage any inflationary pressures through price increases where necessary.

Β 

Half-year results

Β 

IMI will present its half-year results for the period ending 30 June 2026 on 31 July 2026.

Β 

Enquiries to:

Β 

Edward Hann

IMI

Tel: +44 (0)7977 354 810

Faeth Birch

FGS Global

Tel: +44 (0)7768 943 171

James Gray

FGS Global

Tel: +44 (0)7814 379 412

IMI-UK@fgsglobal.com

Β 

A conference call for analysts and investors will be held at 08:00 BST today to discuss this statement. To access the call, please register using the link:

Β 

https://www.netroadshow.com/events/login/1PeTHmohVhEQqO7QvJPq5Kz1eqlYHIsGbuaVE

Β 

Β 

Β 

Β 

Notes

Β 

IMI plc is a global leader in fluid and motion control. Its innovative solutions, built around valves and actuators, enable vital sectors to become safer, more productive and more energy efficient. IMI combines world-class applications engineering expertise with a continued focus on commercial excellence, market-led innovation and continuous improvement to solve its customers' most acute engineering problems. IMI employs approximately 10,000 people, has manufacturing facilities in 18 countries and operates a global service network. IMI is a member of the FTSE 100 and is listed on the London Stock Exchange. Further information is available at www.imiplc.com.

Β 

References to adjusted figures reflect figures as reported to management and do not include the impact of adjusting items. References to organic changes are on a constant currency basis and exclude disposals and acquisitions.

Β 

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF751R30.

Β 

Brand materials can be found here.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTAKDBKPBKDDPD
Date   Source Headline
1st May 201511:19 amRNSTotal Voting Rights
17th Apr 20153:13 pmRNSDirector/PDMR Shareholding
15th Apr 201512:18 pmRNSDirector/PDMR Shareholding
1st Apr 20159:57 amRNSTotal Voting Rights
26th Mar 20153:49 pmRNSAnnual Financial Report
25th Mar 20153:22 pmRNSDirector/PDMR Shareholding
19th Mar 20152:47 pmRNSDirector/PDMR Shareholding
18th Mar 20157:00 amRNSChairman Appointment
11th Mar 20151:37 pmRNSDirector/PDMR Shareholding
9th Mar 201511:02 amRNSAppointment of Divisional Managing Director
6th Mar 20159:39 amRNSDirector Declaration
3rd Mar 20152:22 pmRNSDirector Declaration
2nd Mar 201511:25 amRNSTotal Voting Rights
27th Feb 20157:00 amRNSFinal Results
11th Feb 20152:19 pmRNSDirector/PDMR Shareholding
2nd Feb 201510:26 amRNSTotal Voting Rights
22nd Jan 20154:39 pmRNSHolding(s) in Company
14th Jan 20153:10 pmRNSDirector/PDMR Shareholding
6th Jan 201511:07 amRNSBlocklisting Interim Review
2nd Jan 20153:37 pmRNSCompletion of Bopp & Reuther acquisition
2nd Jan 201512:03 pmRNSTotal Voting Rights
17th Dec 20147:06 amRNSChairman announcement
10th Dec 20143:00 pmRNSDirector/PDMR Shareholding
1st Dec 201411:13 amRNSTotal Voting Rights
27th Nov 20144:10 pmRNSHolding(s) in Company
14th Nov 20147:00 amRNSAcquisition announcement
14th Nov 20147:00 amRNSInterim Management Statement
12th Nov 20142:00 pmRNSDirector/PDMR Shareholding
3rd Nov 201410:02 amRNSTotal Voting Rights
15th Oct 201412:39 pmRNSDirector/PDMR Shareholding
6th Oct 20144:52 pmRNSHolding(s) in Company
6th Oct 20141:00 pmRNSSale of non-core businesses
1st Oct 201410:31 amRNSDirectorate Change
1st Oct 20149:50 amRNSTotal Voting Rights
23rd Sep 20143:15 pmRNSDirector/PDMR Shareholding
23rd Sep 20147:00 amRNSFinance Director Succession
22nd Sep 20144:34 pmRNSDirector/PDMR Shareholding
10th Sep 20143:41 pmRNSDirector/PDMR Shareholding
1st Sep 201412:45 pmRNSTotal Voting Rights
13th Aug 20143:34 pmRNSDirector/PDMR Shareholding
4th Aug 20143:58 pmRNSDirector/PDMR Shareholding
1st Aug 201410:13 amRNSTotal Voting Rights
1st Aug 20147:00 amRNSHalf Yearly Report
9th Jul 20142:07 pmRNSDirector/PDMR Shareholding
2nd Jul 20141:58 pmRNSBlocklisting Interim Review
1st Jul 201410:46 amRNSTotal Voting Rights
17th Jun 20144:35 pmRNSHolding(s) in Company
11th Jun 20141:41 pmRNSDirector/PDMR Shareholding
11th Jun 20141:33 pmRNSDirector Declaration
2nd Jun 201411:09 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.